secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001682852-23-000018
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q1 revenue $1.9B, net income $79M, reiterates $5B FY sales guidance
---------------------------------------------------------------------------

- Q1 revenue $1.9B (down 69% YoY); GAAP net income $79M ($0.19 EPS) vs $3.7B ($8.58 EPS) in Q1 2022.
- Cost of sales 43% of product sales vs 17% prior year; includes $148M inventory write-downs and $135M idle capacity charges.
- R&D spending surged 104% to $1.1B, driven by RSV, flu, CMV programs; total 2023 OpEx guided ~$6B.
- RSV vaccine (mRNA-1345) met primary endpoint in older adults; expects regulatory submission and 2024 launch.
- COVID-19 vaccine sales from APAs still projected at $5B for 2023; Q2 sales expected $0.2-0.3B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000018/0001682852-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000018/mrna-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001682852-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer